Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13

Citigroup analyst Yigal Nochomovitz has maintained a 'Sell' rating on Sarepta Therapeutics (NASDAQ: SRPT) while raising the price target from $9 to $13. This adjustment reflects a revised outlook on the company's stock performance.